23andMe Investor Day Presentation Deck

Focusing on Translational Research to Link Targets and Outcomes VALUE TO PATIENTS meaningful benefit TARGET/MOA BENCH PATHOPHYSIOLOGY identify indications and develop outcome measures most relevant to biologically compelling targets develop targets that are most relevant to unmet needs in existing indications tettet ** unselected population N U biomarker level ok okok ·oK CLINICAL ENDPOINTS Townsend & Arron, Nat Rev Drug Discov 15:517 (2016) BEDSIDE biomarker-defined phenotype A pathway A' clinical manifestation A" biomarker-defined phenotype B pathway B' clinical manifestation B" Copyright © 2022 23andMe, Inc. 23andMe® 19

View entire presentation